Skip to Content

Equi-Phar Phenylbutazone Injection 20%

This page contains information on Equi-Phar Phenylbutazone Injection 20% for veterinary use.
The information provided typically includes the following:
  • Equi-Phar Phenylbutazone Injection 20% Indications
  • Warnings and cautions for Equi-Phar Phenylbutazone Injection 20%
  • Direction and dosage information for Equi-Phar Phenylbutazone Injection 20%

Equi-Phar Phenylbutazone Injection 20%

This treatment applies to the following species:
Company: Vedco


For Horses Only

ANADA 200-126, Approved by FDA

Equi-Phar Phenylbutazone Injection 20% Caution

Federal law restricts this drug to use by or on the order of a licensed veterinarian.


Phenylbutazone Injection (phenylbutazone) is a synthetic, nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound’s anti-inflammatory properties.

Chemically, phenylbutazone is 4-butyl-1,2-diphenyl- 3,5-pyrazolidinedione. It is a pyrazolon derivative entirely unrelated to the steroid hormones, and has the following structural formula:

BACKGROUND PHARMACOLOGY: Kuzell,1,2,3 Payne,4 Fleming,5 and Denko6 demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis, and various other rheumatoid disorders in man. Anti-rheumatic and anti-inflammatory activity has been well established by Fabre,7 Domenjoz,8 Wilhelmi,9 and Yourish.10

Camberos14 reported favorable results with phenylbutazone following intermittent treatment of Thoroughbred horses for arthritis and chronic arthrosis (e.g., osteoarthritis of medial and distal bones of the hock, arthritis of the stifle and hip, arthrosis of the spine, chronic hip pains, chronic pain in trapezius muscles, and generalized arthritis). Results were less favorable in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Sutter15 reported favorable response in chronic equine arthritis, fair results in a severely bruised mare, and poor results in two cases where the condition was limited to the third phalanx.

Equi-Phar Phenylbutazone Injection 20% Indications

For relief of inflammatory conditions associated with the musculoskeletal system in horses.


Treated animals should not be slaughtered for food purposes. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. Use with caution in patients who have a history of drug allergy.


Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man; fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of two weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate countermeasures.

In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.


Equi-Phar Phenylbutazone Injection 20% Dosage And Administration:


INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily. Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.


1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.

2. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.

3. In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals. Reduce dosage as symptoms regress. In some cases, treatment may be given only when symptoms appear with no need for continuous medication. If long-term therapy is planned, oral administration is suggested.

4. Many chronic conditions will respond to phenylbutazone therapy, but discontinuance of treatment may result in recurrence of symptoms.

How Supplied

INJECTION: For Horses only: 100 mL vials, 200 mg/mL (1 g/5 mL).

Each mL contains 200 mg of phenylbutazone, 10.45 mg of benzyl alcohol as preservative, sodium hydroxide to adjust pH to 9.5 to 10.0, and water for injection, Q.S.


1. Kuzell, W.C., Schaffarzick, R.W., Naugler, W.G., and Mankle, E.A.: AMA Arch. Int. Med. 92:646, 1953.

2. Kuzell, W.C., Schaffarzick, R.W., Brown, B., and Mankle, E.A.: Jour. Amer. Med. Assoc. 149:729, 1952.

3. Kuzell, W.C., Schaffarzick, R.W., Calif. Med. 77:319, 1952.

4. Payne, R.W., Shetlar, M.R., Farr, C., Hellbaum, A.A. and Ishmael, W.K.T.: J. Lab. Clin. Med. 45:331, 1955.

5. Fleming, J., and Will, G.: Ann. Rheumat. Dis. 12:95, 1953.

6. Denko, C.W., and Rumi, D.: Amer. Practit. 6:1865, 1955.

7. Fabre, J. and Berger, A: Semaine Hop. (Paris) 31:87, 1955.

8. Domenjoz, R., Theobald, W. and Morsdorf, K.: Arzneimittel-Forsch. 5:488, 1955.

9. Wilhelmi, G., and Pulver, R.: Arzneimittel-Forsch. 5:221, 1955.

10. Yourish, N., Paton, B., Brodie, B.B., and Burns, J.J.: AMA Arch. Ophth. 53:264, 1955.

11. Lieberman, L.L.: Jour. Amer. Vet. Assoc. 125:128, 1954.

12. Joshua, J.O.: Vet. Rec. 68:60 (Jan. 21), 1956.

13. Ogilvie, F.B., and Sutter, M.D.: Vet. Med. 52:492-494, 1957.

14. Camberos, H.R.: Rev. Med. Vet. (Buenos Aires); 38:9, 1956.

15. Sutter, M.D.: Vet. Med. 53:83 (Feb.), 1958.


Manufactured for VEDCO, Inc., St. Joseph, MO 64507

600043 Rev0906




100 mL


600043 Rev0706

CPN: 10940872

Telephone:   816-238-8840
Toll-Free:   888-708-3326 (888-70VEDCO)
Fax:   816-238-1837
Every effort has been made to ensure the accuracy of the Equi-Phar Phenylbutazone Injection 20% information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2020 Animalytix LLC. Updated: 2020-10-21